NATCOPHARM - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 4.2
| Stock Code | NATCOPHARM | Market Cap | 19,626 Cr. | Current Price | 1,096 ₹ | High / Low | 1,135 ₹ |
| Stock P/E | 13.1 | Book Value | 462 ₹ | Dividend Yield | 0.55 % | ROCE | 31.8 % |
| ROE | 27.5 % | Face Value | 2.00 ₹ | DMA 50 | 1,014 ₹ | DMA 200 | 945 ₹ |
| Chg in FII Hold | 2.21 % | Chg in DII Hold | 0.07 % | PAT Qtr | 107 Cr. | PAT Prev Qtr | 501 Cr. |
| RSI | 60.1 | MACD | 27.3 | Volume | 4,68,934 | Avg Vol 1Wk | 5,36,362 |
| Low price | 752 ₹ | High price | 1,135 ₹ | PEG Ratio | 0.08 | Debt to equity | 0.03 |
| 52w Index | 89.8 % | Qtr Profit Var | -14.4 % | EPS | 83.8 ₹ | Industry PE | 30.1 |
📊 Financials: NATCOPHARM demonstrates strong fundamentals with ROE at 27.5% and ROCE at 31.8%, supported by very low debt-to-equity (0.03). EPS is robust at ₹83.8, and the company maintains a healthy book value of ₹462. However, quarterly PAT dropped sharply (₹107 Cr vs ₹501 Cr), reflecting earnings volatility.
💹 Valuation: The stock trades at a P/E of 13.1, well below the industry average of 30.1, indicating undervaluation. PEG ratio of 0.08 highlights attractive growth-adjusted valuation. Dividend yield of 0.55% provides modest income support. Overall, intrinsic value appears favorable compared to peers.
🏭 Business Model: NATCOPHARM operates in the pharmaceutical sector, with strengths in generics and niche therapies. Its competitive advantage lies in strong R&D capabilities, efficient capital use, and global market reach. However, earnings volatility and regulatory risks remain challenges.
📈 Entry Zone: Attractive entry would be near ₹1,020–₹1,050, aligning with support levels and fair valuation. Current price (₹1,096) is above both 50 DMA (₹1,014) and 200 DMA (₹945), suggesting bullish momentum. Long-term investors may accumulate gradually, with focus on sustained earnings recovery.
Positive
- Strong ROE (27.5%) and ROCE (31.8%).
- Low debt-to-equity ratio (0.03).
- EPS of ₹83.8 reflects strong earnings base.
- FII holdings increased (+2.21%), showing foreign investor confidence.
Limitation
- Quarterly PAT dropped sharply (₹107 Cr vs ₹501 Cr).
- Profit variation (-14.4%) indicates earnings volatility.
- Volume slightly below average, showing reduced trading activity.
Company Negative News
- Sharp decline in quarterly profits.
- Earnings volatility raises sustainability concerns.
Company Positive News
- Strong fundamentals with attractive valuation (P/E 13.1 vs industry 30.1).
- FII inflows (+2.21%) reflect investor confidence.
- Robust R&D and global market presence.
Industry
- Pharmaceutical industry remains resilient with long-term growth potential.
- Industry P/E at 30.1 highlights NATCOPHARM’s undervaluation.
- Regulatory risks and competition affect margins.
Conclusion
⚖️ NATCOPHARM shows strong fundamentals with high efficiency, low debt, and attractive valuation. Despite recent profit volatility, long-term prospects remain favorable. Entry is attractive near ₹1,020–₹1,050. Holding is viable for long-term investors, with focus on earnings recovery and sustained growth.